Melatonin Protects Cholangiocytes from Oxidative Stress-Induced Proapoptotic and Proinflammatory Stimuli via miR-132 and miR-34.
Animals
Apoptosis
/ drug effects
Bile Ducts
/ cytology
Biomarkers
Cells, Cultured
Epithelial Cells
/ metabolism
Gene Expression Regulation
/ drug effects
Humans
Immunohistochemistry
Liver
/ drug effects
Liver Cirrhosis, Biliary
/ blood
Melatonin
/ metabolism
MicroRNAs
/ genetics
Oxidative Stress
/ drug effects
Protective Agents
/ pharmacology
apoptosis
melatonin
micro RNA
oxidative stress
primary biliary cholangitis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
18 Dec 2020
18 Dec 2020
Historique:
received:
30
11
2020
revised:
14
12
2020
accepted:
15
12
2020
entrez:
23
12
2020
pubmed:
24
12
2020
medline:
17
3
2021
Statut:
epublish
Résumé
Biosynthesis of melatonin by cholangiocytes is essential for maintaining the function of biliary epithelium. However, this cytoprotective mechanism appears to be impaired in primary biliary cholangitis (PBC). MiR-132 has emerged as a mediator of inflammation in chronic liver diseases. The effect of melatonin on oxidative stress and bile acid-induced apoptosis was also examined in cholangiocyes overexpressing miR506, as a PBC-like cellular model. In PBC patients the serum levels of melatonin were found increased in comparison to healthy controls. Whereas, in cholangiocytes within cirrhotic PBC livers the melatonin biosynthetic pathway was substantially suppressed even though the expressions of melatonin rate-limiting enzyme aralkylamine N-acetyltransferase (AANAT), and CK-19 (marker of cholangiocytes) were enhanced. In cholangiocytes exposed to mitochondrial oxidative stress melatonin decreased the expression of proapoptotic stimuli (PTEN, Bax, miR-34), which was accompanied by the inhibition of a pivotal mediator of inflammatory response Nf-κB-p65 and the activation of antiapoptotic signaling (miR-132, Bcl2). Similarly, melatonin reduced bile acid-induced proapoptotic caspase 3 and Bim levels. In summary, the insufficient hepatic expression of melatonin in PBC patients may predispose cholangiocytes to oxidative stress-related damage. Melatonin, via epigenetic modulation, was able to suppress NF-κB signaling activation and protect against biliary cells apoptotic signaling.
Identifiants
pubmed: 33352965
pii: ijms21249667
doi: 10.3390/ijms21249667
pmc: PMC7766218
pii:
doi:
Substances chimiques
Biomarkers
0
MIRN132 microRNA, human
0
MIRN34 microRNA, human
0
MicroRNAs
0
Protective Agents
0
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Science Centre in Poland
ID : grant no. 2015/17/B/NZ5/02541
Références
Bone Res. 2020 Feb 18;8:10
pubmed: 32133213
Gene Expr. 2017 Feb 10;17(2):155-171
pubmed: 27412505
J Biol Chem. 2015 Jan 2;290(1):184-96
pubmed: 25378392
Mol Cell Endocrinol. 2016 Nov 15;436:59-67
pubmed: 27452798
Ann N Y Acad Sci. 2005 Dec;1057:372-83
pubmed: 16399907
Hepatology. 2012 Aug;56(2):687-97
pubmed: 22383162
J Autoimmun. 2007 Sep-Nov;29(2-3):78-86
pubmed: 17544621
Annu Rev Pathol. 2013 Jan 24;8:303-30
pubmed: 23347352
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7997-E8006
pubmed: 28874589
Int J Mol Sci. 2013 Apr 22;14(4):8638-83
pubmed: 23609496
Mol Med Rep. 2015 Oct;12(4):5709-14
pubmed: 26252661
Am J Physiol Gastrointest Liver Physiol. 2014 Nov 1;307(9):G894-904
pubmed: 25214401
Cell Death Differ. 2010 Feb;17(2):193-9
pubmed: 19461653
Exp Gerontol. 2010 Dec;45(12):950-6
pubmed: 20817086
Lab Invest. 2010 Oct;90(10):1437-46
pubmed: 20548288
Liver Int. 2015 Jan;35(1):263-74
pubmed: 25181933
FASEB J. 2017 Oct;31(10):4305-4324
pubmed: 28634212
Biochim Biophys Acta. 1999 Oct 18;1472(1-2):206-14
pubmed: 10572942
Oncol Rep. 2015 Mar;33(3):1443-9
pubmed: 25606968
Int J Mol Sci. 2017 Jan 29;18(2):
pubmed: 28146070
J Hepatol. 2017 Jul;67(1):145-172
pubmed: 28427765
J Pineal Res. 2014 Jan;56(1):20-30
pubmed: 24117795
Hepatology. 2013 Mar;57(3):1130-41
pubmed: 23080076
Molecules. 2019 Aug 25;24(17):
pubmed: 31450679
J Pineal Res. 2017 Aug;63(1):
pubmed: 28398673
J Pineal Res. 2013 Jan;54(1):1-14
pubmed: 22725668
JCI Insight. 2017 Mar 9;2(5):e90780
pubmed: 28289714
J Pineal Res. 2002 Aug;33(1):48-56
pubmed: 12121485
Cell Biol Toxicol. 2010 Dec;26(6):541-51
pubmed: 20429028
Biosci Rep. 2019 Jan 15;39(1):
pubmed: 30578379
J Pharmacol Exp Ther. 1995 Feb;272(2):930-8
pubmed: 7853211
FASEB J. 2010 Oct;24(10):3603-24
pubmed: 20534884
J Pineal Res. 2012 Mar;52(2):217-27
pubmed: 21884551
Neurol Res. 2020 May;42(5):405-414
pubmed: 32174265
Hepatology. 2014 May;59(5):1944-53
pubmed: 24375552
J Pineal Res. 2017 Aug;63(1):
pubmed: 28370493
Liver Int. 2013 Feb;33(2):231-8
pubmed: 23295054
Sci Rep. 2017 Mar 23;7:44769
pubmed: 28333129
Life Sci. 1999 Oct 29;65(23):2523-9
pubmed: 10622237
Mol Metab. 2020 Jan;31:150-162
pubmed: 31918917
J Pineal Res. 2008 Nov;45(4):532-40
pubmed: 19012662
FASEB J. 2015 Sep;29(9):3863-75
pubmed: 26045547
Eur J Pharmacol. 2009 Aug 15;616(1-3):287-92
pubmed: 19576882
Cell Cycle. 2009 Mar 1;8(5):712-5
pubmed: 19221490
J Biochem Mol Toxicol. 2012 Feb;26(2):79-86
pubmed: 22162084
Gastroenterology. 2010 Feb;138(2):705-14, 714.e1-4
pubmed: 19843474
Biofactors. 2018 Nov;44(6):609-618
pubmed: 29322615
Clin Exp Immunol. 2012 Jun;168(3):279-84
pubmed: 22519590
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):542-52
pubmed: 23689081
Lab Invest. 2017 Nov;97(11):1385-1396
pubmed: 28892096
J Neurochem. 2004 Jul;90(2):442-54
pubmed: 15228600
Hepatology. 2018 Apr;67(4):1420-1440
pubmed: 28922472